MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
Bank of America Corporation filed an amended Schedule 13G reporting beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock. This represents 4.0% of the class, based on 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics’ May 13, 2026 Form 10-Q.
Bank of America reports no sole voting or dispositive power and shared voting and dispositive power over all 2,556,475 shares, held through wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA. The filing confirms ownership of 5 percent or less of the class.
BlackRock, Inc. reports beneficial ownership of 4,503,913 shares of MACROGENICS INC common stock on a Schedule 13G, representing 7.1% of the class as of June 30, 2026. This stake is held by certain BlackRock business units under SEC Release No. 34-39538.
BlackRock has sole voting power over 4,447,312 shares and sole dispositive power over 4,503,913 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no individual client holds more than five percent of MacroGenics’ outstanding common shares.
MacroGenics, Inc. reported an update on its ongoing Phase 1 study of MGC026, a B7-H3–directed antibody-drug conjugate for advanced solid tumors. Dose escalation from 1 mg/kg to 9 mg/kg q3W has been completed, and a 7.5 mg/kg q3W dose is being evaluated in four tumor-specific cohorts, including squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer, melanoma and soft tissue sarcoma.
The SCCHN cohort, designed under Simon’s two-stage design with a planned 40-patient enrollment, has met the pre-specified Stage 1 response threshold and is now enrolling Stage 2. As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion. No cases of interstitial lung disease or ocular toxicity had been reported, and evidence of anti-tumor activity was observed in several indications. MacroGenics plans to present dose-escalation and preliminary cohort data at the ESMO 2026 Congress in Madrid, including a poster on MGC026 on October 23, 2026 and a separate poster on lorigerlimab in advanced gynecologic cancers on October 26, 2026.
MacroGenics, Inc. received an amended Schedule 13G indicating that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 2,374,296 shares of MacroGenics common stock. This represents 3.7% of the outstanding common stock.
The reporting persons disclose no sole voting or dispositive power and shared voting and shared dispositive power over 2,374,296 shares. They state that the securities are held by entities subject to their voting control or investment discretion and note that the filing should not itself be construed as an admission of beneficial ownership. They also confirm that they now own 5% or less of this class of securities.
MacroGenics, Inc. reported that board member Karen Ferrante, M.D. has decided to resign from its board of directors. She notified the board on July 1, 2026, with her resignation effective September 1, 2026. The company states that her decision is for personal reasons and not due to any disagreement related to operations, policies, or practices. MacroGenics publicly thanked Dr. Ferrante for her contributions to the company.
MacroGenics, Inc. completed the sale of its GMP drug substance manufacturing and CDMO operations in Maryland to Bora Pharmaceuticals and Bora Biologics for $122.5 million in cash, subject to customary post-closing adjustments. Net cash proceeds recognized in the pro forma balance sheet are $110.7 million after working capital adjustments and estimated $8.0 million of transaction costs.
The purchaser assumed responsibility for the CDMO operations, including the Rockville manufacturing site and Frederick warehouse, and hired approximately 140 former MacroGenics employees. MacroGenics and Bora also entered into a supply agreement under which Bora will provide process development and drug substance production for MacroGenics’ pipeline.
On a pro forma basis for the year ended December 31, 2025, total revenue excluding the divested contract manufacturing business is $96.9 million, and net income is $46.3 million, compared with a historical net loss of $74.6 million. The pro forma gain on derecognition of the purchased assets is $109.7 million on January 1, 2025 and $106.1 million on March 31, 2026.
MacroGenics, Inc. reported a Schedule 13G showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander have shared voting and dispositive power over 3,435,504 shares of MacroGenics common stock, equal to 5.4% of the class as shown with a 06/01/2026 time anchor. The filing is a joint filing and includes a Joint Filing Agreement dated June 4, 2026.
MACROGENICS INC director Federica F. O'Brien reported equity compensation and an option exercise. On May 18, 2026, 3,750 restricted stock units vested and were exercised into 3,750 shares of common stock, leaving her with 14,750 common shares directly owned.
On May 19, 2026, she received a grant of 3,750 new restricted stock units and a stock option for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. The option vests in monthly 1/12th increments, while the new RSUs vest one year from grant or the day prior to the next annual meeting, if earlier. These are compensation-related awards, not open-market purchases.
MACROGENICS INC director Scott Thomas Jackson reported equity awards and an RSU vesting. On May 19, 2026, he received a stock option for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. He was also granted 3,750 restricted stock units (RSUs), each representing one share of common stock and scheduled to vest one year after grant or the day before the next annual meeting, if earlier.
On May 18, 2026, 3,750 RSUs vested and were exercised into 3,750 shares of common stock. Following these transactions, Jackson directly holds 14,750 shares of common stock, plus the new 3,750 RSUs and the 22,000 stock options. These are compensation-related awards and an RSU-to-share conversion, not open‑market purchases or sales.